$BAX (Baxter International Inc.)

$BAX {{ '2015-12-01T17:30:43+0000' | timeago}} • SEC

During the first nine months of 2015, $BAX borrowed $1.5Bil which is outstanding as of Sept. 30, 2015, under its $1.8Bil US dollar-denominated revolving credit facility at a weighted avg. interest rate of 1.33%. This facility is scheduled to mature in Dec. 2015. As of Dec. 31, 2014 there were no borrowings under any of $BAX's credit facilities.

$BAX {{ '2017-07-18T14:01:55+0000' | timeago}} • Announcement

The BoD of $BAX declared a quarterly dividend of $0.16 per share of its common stock. The dividend is payable on Oct 2, 2017, to stockholders of record as of Sept 1, 2017.

$BAX {{ '2017-07-17T20:58:53+0000' | timeago}} • Announcement

$BAX appointed Cathy Smith, EVP and CFO of $TGT, to its BoD, bringing the total number of directors serving the company at this time to 13. Smith now also serves on $BAX's Audit Committee.

$BAX {{ '2017-06-26T13:13:55+0000' | timeago}} • Announcement

$BAX has announced a bi-directional integration between its software solution DoseEdge Pharmacy Workflow Manager and the Epic Willow Inpatient Pharmacy System. The integration will help hospitals efficiently comply with requirements from the Centers for Medicare and Medicaid Services and other insurers.

$BAX {{ '2017-06-14T12:53:57+0000' | timeago}} • Announcement

$BAX recently announced plans to expand its presence in the space with the pending acquisition of Claris Injectables. The acquisition of Claris is expected to close in 2H17. $BAX recently announced a strategic partnership with ScinoPharm to develop, manufacture and commercialize five generic injectables used in cancer treatment.

$BAX {{ '2017-06-14T12:50:42+0000' | timeago}} • Announcement

$BAX agreed with Dorizoe Lifesciences to facilitate accelerated development of more than 20 generic injectable products, including anti-infectives, oncolytics and cardiovascular medicines. Dorizoe will work with $BAX to perform certain product development activities, and $BAX will hold worldwide manufacturing and commercialization rights.

$BAX {{ '2017-06-07T15:22:17+0000' | timeago}} • Announcement

$BAX announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of ready-to-use clindamycin injection in saline in three commonly prescribed formulations. Clindamycin is used to treat serious infections caused by bacteria.

$BAX {{ '2017-06-05T20:30:19+0000' | timeago}} • Announcement

$BAX presented new data demonstrating abilities of its Sharesource remote patient management technology to improve the care of peritoneal dialysis patients and increase dialysis clinic efficiencies. The cloud-based platform offers healthcare providers more accurate and timely visibility to patients’ therapy adherence, allowing timely intervention.

$BAX {{ '2017-06-05T13:03:56+0000' | timeago}} • Announcement

$BAX said data from two independent studies concluded that HDx, or expanded hemodialysis therapy, enabled by the Theranova dialyzer effectively removed small and mid-sized toxins at similar rates when compared to hemodiafiltration (HDF), another type of dialysis.

$BAX {{ '2017-05-02T14:48:04+0000' | timeago}} • Announcement

$BAX BoD has declared a 23% increase in its quarterly dividend rate, from the previous rate of $0.13 per share to $0.16 per share. The dividend is payable on July 3, 2017 to stockholders as of June 2, 2017.

$BAX {{ '2017-04-26T19:39:39+0000' | timeago}} • Webcast

$BAX expects the 20% growth in fluid systems business in the US to come down over time.

$BAX {{ '2017-04-26T19:20:17+0000' | timeago}} • Webcast

$BAX's adjusted operating margin in 1Q17 was up 590 basis points to 16.4%. Growth in the quarter for BAX was impacted by a mid-single-digit decline in hemodialysis globally. Baxter now assumes additional competitors to enter the integrated pharmacy solutions market during 3Q17.

$BAX {{ '2017-04-26T14:18:02+0000' | timeago}} • Infographic

$BAX Baxter International Inc. Earnings AlphaGraphics: Q1 2017 highlights

$BAX {{ '2017-04-26T13:26:46+0000' | timeago}} • Announcement

$BAX's global sales for Hospital Products totaled $1.6Bil in 1Q17, up 7% on both a reported and constant currency basis. Renal sales totaled $896MM, up 1% globally on a constant currency basis.

$BAX {{ '2017-04-26T13:24:33+0000' | timeago}} • Announcement

$BAX's sales within the US were $1.1Bil, advancing 11% on a reported basis in 1Q17. International sales of $1.4Bil declined 1% on a reported basis and were comparable to the prior year on a constant currency basis. Operational sales rose 13% in the US and 2% internationally.

$BAX {{ '2017-04-26T13:21:50+0000' | timeago}} • Announcement

In 2Q17, $BAX expects flat sales growth on a reported basis, or approx 2% on a constant currency basis. It expects earnings from continuing operations, before special items, of $0.55 to $0.57 per share.

$BAX {{ '2017-04-26T13:19:40+0000' | timeago}} • Announcement

$BAX raised its outlook for FY17. It now expects sales growth of approx 1-2% on a reported basis or 2-3% on a constant currency basis. Earnings from continuing operations, before special items, is estimated to be between $2.20 and $2.28 per share.

$BAX {{ '2017-04-26T13:13:54+0000' | timeago}} • Announcement

Healthcare company $BAX said its net income was down 92% to $272MM in 1Q17, even as net sales increased 4% to $2.47Bil. However, excluding special items, income from continuing operations was up 60% to $318MM, or $0.58 per share. GAAP EPS declined to $0.49, from $6.12 in the year-over period.

$BAX {{ '2017-02-01T14:58:20+0000' | timeago}} • Webcast

$BAX reported that emerging markets grew 3% in 4Q16 and all of the exits are happening in emerging markets. The company is exiting some businesses in India, Turkey and Venezuela. In Greater China, $BAX is up 6%. $BAX is bullish about Latin America and extended the investment there.

$BAX {{ '2017-02-01T14:47:26+0000' | timeago}} • Webcast

In the next 3 to 5 years, $BAX expects to launch 100 different new molecules into the market from Claris acquisition. The company has also plans to sign several different collaborations and partnership agreements in the next 30 days.

$BAX {{ '2017-02-01T14:41:14+0000' | timeago}} • Webcast

$BAX believes that share buyback will offset dilution. The company added that there is a few $100MM of buyback embedded in 2017 guidance. The repurchase will depend on the evolution of the share price relative to the intrinsic value of the company.

Recent Transcripts

AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
ABC (AmerisourceBergen Corporation)
Thursday, May 4 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, May 3 2017 - 9:30pm
ITRI (Itron, Inc.)
Wednesday, May 3 2017 - 9:00pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
AMGN (Amgen Inc)
Wednesday, April 26 2017 - 9:00pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, April 26 2017 - 12:30pm

AlphaGraphics you may like